The recent years have witnessed a rapid expansion and application of functional somatostatin receptor-targeted imaging and therapy in the clinical management of metastatic or inoperable neuroendocrine tumors (NETs). This approach now plays a pivotal role in the clinical decision making of this group of patients, given the highly targeted and effective nature of peptide receptor radionuclide therapy (PRRT) in tumors with substantial somatostatin cell surface receptor expression and its noted tolerability with minimal side effects. The popularity of the therapeutic option has steadily increased and is now frequently considered among the multimodal management strategies that include [1, 2] : (i) Cytoreductive surgery (if feasible), (ii) medical therapy (encompasses cold somatostatin analogs, targeted agents and chemotherapy), (iii) locoregional ablative procedures such as radiofrequency ablation (RFA), selective hepatic transcatheter arterial embolization (TAE), chemoembolization (TACE), selective internal radiotherapy (SIRT), and laser-induced thermotherapy (LITT). One of the salient decision-making factors for choosing the appropriate therapy has been the tumor grade, which is based upon the proliferation index (also known as Ki-67 labeling index, a marker for cellular proliferation). Some of the reasons PRRT is preferred over the newer targeted agents available (everolimus and sunitinib) include the cost of these new drugs, toxicity, and the need to remain on these drugs until progression, while PRRT is a one-off procedure completed in few sittings. In this article, we explore how functional molecular imaging correlates with the histopathological characteristics of a tumor and whether patient-specific, personalized medicine can be better employed in the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET), based upon functional imaging information. Ideally, this imaging would provide a global picture of the lesions and the disease, contributing to selection of the correct treatment option and helping to define the disease prognosis.
Tumor proliferation index and NETs: implications for clinical management decisions in metastatic NETs
Histological tumor grading, along with stage and age, are strong predictors of overall outcome in NETs, of which the former is of pivotal importance in prognostic risk stratification and has been frequently utilized for treatment decisionmaking. Irrespective of the endeavors and different systems of classifications by various groups, the Ki-67 labeling index (LI; depicting Ki-67-positive tumor cells, the fraction that are in the proliferative phases of the cell cycle, i.e., G 1 , S, G 2 , and mitosis) has been the major determinant of histological grading of NETs [3] [4] [5] [6] [7] [8] [9] . In the practical scenario, attending physicians are better versed with the MIB-1 labeling index (more commonly observed in histopathology reports, and has essentially replaced the original Ki-67 index in practice), which is directed against different epitopes of the same proliferationrelated antigen MKI67 and has the advantage of being estimated on formalin-fixed, paraffin-embedded sections. Current guidelines (ENETS, WHO), of course, refer to the Ki-67 index as the standard nomenclature, assessed in 2,000 tumor cells in areas having the highest nuclear labeling [6, 7] .
The standard indication of peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin receptor analogues ( 177 Lu/ 90 Y-labelled DOTA-TOC/ TATE) has been advanced/metastatic/inoperable welldifferentiated grade 1 and 2 NETs (this corresponds to Mib1 (Ki-67) LI of up to 20 %) that express somatostatin receptor positivity, evaluated by somatostatin receptor-based imaging (SRI) with 68Ga-DOTA-TOC/ TATE/NOC PET-CT or 99mTc-HYNIC-TOC scintigraphy or 111In-octreoscan [1, 2, 10] . The former imaging approach is preferable due to its superior resolution and hence, better sensitivity and the advantage of quantification. The latter approach, along with SPECT imaging, can be conveniently employed in centers that do not possess the 68Ge-68Ga generator or that do not have a PET-CT facility [11] . Chemotherapy is the preferred option in high-grade (G3) neuroendocrine carcinoma (NEC), with increasing proliferation index more preference towards the combination chemotherapeutic approach is given because of better chemosensitivity of the tumor [1, 2, 10, 12] .
Functional molecular imaging and MiB 1 index: the correlation
Both somatostatin receptor-targeted molecular imaging (SRI) and FDG PET/CT imaging have been utilized for the evaluation of NETs, though the former is the major decision-making scan used for evaluating somatostatin receptor positivity of the lesions and deciding upon the suitability of PRRT. On a graded visual analysis of the diagnostic somatostatin receptor-targeted imaging, tracer uptake in metastatic lesions is a more important imaging determinant than the normal hepatic uptake for selecting the patient for PRRT [10, [12] [13] [14] . FDG-PET/CT, on the other hand, assesses glycolytic metabolism, and its higher uptake is associated with tumor aggressiveness [15] . A dichotomous behavior exists between both of these tracers in well-differentiated and poorly differentiated NETs [16, 17] , where the former is more positive with somatostatin-targeted imaging and the latter with FDG-PET/CT. Hence, a combination dual-tracer approach encompassing somatostatin receptor and FDG PET imaging assessing the somatostatin receptor cell surface (SSTR) expression and glycolytic metabolism, respectively, can be utilized to enhance treatment selection as well as disease prognosis in a more scientific manner.
The possible clinical implications of dual-tracer molecular imaging vis-a-vis the tumor proliferation index: will the former take the upper hand for prognosis and guiding individualized therapy?
We herein enumerate the possible clinical areas where the dual-tracer imaging information can be potentially useful to augment individualized clinical decision making in NET with an emphasis on PRRT.
[a] Assessing disease biology on a continuous scale at intermediate Mib1 (Ki-67) indices:
While total discordance between the two tracers at extremes of tumor differentiation is the usual observation, they are not so clear-cut at the intermediate indices. LI was reported to be 1-2 % and the serum Cg A was 1,375 ng/ml. The recurrent mass and the hepatic lesion showed high-grade uptake in SRI but negligible uptake on PET-CT (i.e., total discordance between SRI and FDG-PET/CT) observed in our practice (in patients who had undergone PRRT), that while most patients with less than 2 % Mib 1 LI demonstrated a near-total discordance with high somatostatin receptor positivity and little or absent FDG activity, the uptake and the lesion positivity on FDG increased with increasing Mib1 (Ki-67) LI (partial concordance between FDG and SRI). Total concordance of the lesions was observed in virtually all lesions above Mib1 (Ki-67) LI of 15 % (unpublished data). However, discordance between the imaging results and proliferation index does exist, in which case, the in-vivo imaging shows discrete advantages compared to the histopathology alone (addressed below, separately). Thus, when correlated, the molecular imaging with the dual-tracer approach has the potential to show the overall biology on a continuum where high FDG avidity of a lesion signifies poorer prognosis (Figs. 1, 2 , and 3).
[b] Assessing intra-and interlesional heterogeneity in metastatic lesions:
Somatostatin Receptor Imaging 18F-FDG PET CT The ability to perform the imaging assessment as a whole-body study is a discrete advantage compared to single-site biopsy. Both intra-and intertumoral heterogeneity are known to exist in cancer [17] , and the same can be encountered in NETs as well. Thus, in the same individual, different lesions (or different parts of a same large lesion) can demonstrate different grades of tracer uptake indicating different tumor biology, and hence different aggressiveness. Thus, high FDG uptake would suggest an aggressive behavior and the possibility of treatment refractoriness of the cells at the site, whereas low uptake would indicate a biologically indolent lesion (Fig. 2) . In the scenario of ongoing treatment, appearance and increase of FDG uptake in a particular lesion among several lesions would suggest the development of treatment resistant clones at that site.
[c] Discordance between molecular imaging and tumor proliferation index of the primary
The intralesional clonal heterogeneity in the primary can, at times, lead to discordance between the molecular imaging characteristics and the Mib1 (Ki-67) index obtained. The limitations of relying on single-site histopathology should be kept in mind when one encounters such discordance, where the molecular imaging would be representative of the global phenotype of the tumor, thus predicting the treatment outcome more appropriately. (Figure 4 ). With the increasing popularity and reliance on PRRT among the medical oncology community, efforts have been made to extend its indications beyond the suggested limit of Mib1 (Ki-67) LI of 20 % [2, 18] . Thus, though the joint IAEA, EANM, and SNMMI practical guidelines as well as the standard practice on PRRT in NETs [10, 19, 20] all use 20 % as the cutoff, the recently published ESMO Clinical Practice Guidelines [2] have extended the recommended upper limit of Ki-67 LI to 30 %. This is a grey area where considerable practice diversity exists. Adopting a dual-tracer approach could support better individualization of therapy selection in this group, where a high uptake on SRI and low FDG uptake would favor PRRT and the opposite would indicate addition of chemotherapy.
Conclusion
Here, we have taken a critical look at the potential clinical utilities of a dual-tracer imaging approach in the evaluation of patients with NET and the advantages it can offer in managing these patients. NETs are very heterogeneous, thus we believe that functional imaging may offer the important potential to biologically characterize neuroendocrine tumors such that their treatments could be better individualized and optimized. Dual-tracer imaging was a correct predictor of tumor aggressiveness, though the MiB1 LI was reportedly low therapy, disease prognosis, and overall management of neuroendocrine tumors.
